on CROSSJECT (EPA:ALCJ)
Crossject: Update on voting rights and shares as of January 31, 2025
The pharmaceutical company CROSSJECT, specializing in the development of drugs for emergencies, published in Dijon on March 10, 2025 an update concerning the total number of voting rights and shares as of January 31, 2025. This publication complies with the requirements of Articles 223-16 of the AMF General Regulations and L.233-8 II of the French Commercial Code.
As of February 28, 2025, CROSSJECT had 45,539,227 shares comprising its share capital. The number of theoretical voting rights amounted to 55,492,332, while the exercisable voting rights were slightly lower, amounting to 55,352,017, due to 123,310 shares deprived of voting rights.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CROSSJECT news